Genexine (Korea) Buy Hold or Sell Recommendation
| 095700 Stock | KRW 5,840 210.00 3.47% |
Assuming the 90 days trading horizon and your above-average risk tolerance, our recommendation regarding Genexine is 'Strong Sell'. Macroaxis provides Genexine buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding Genexine positions.
Check out Genexine Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Genexine and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Genexine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Genexine |
Execute Genexine Buy or Sell Advice
The Genexine recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Genexine. Macroaxis does not own or have any residual interests in Genexine or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Genexine's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Genexine Trading Alerts and Improvement Suggestions
| Genexine generated a negative expected return over the last 90 days | |
| Genexine has high historical volatility and very poor performance | |
| The company reported the revenue of 36.83 B. Net Loss for the year was (48.56 B) with profit before overhead, payroll, taxes, and interest of 9.76 B. | |
| Genexine has accumulated about 27.8 B in cash with (12.75 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 687.14. | |
| Roughly 21.0% of the company shares are owned by insiders or employees |
Genexine Returns Distribution Density
The distribution of Genexine's historical returns is an attempt to chart the uncertainty of Genexine's future price movements. The chart of the probability distribution of Genexine daily returns describes the distribution of returns around its average expected value. We use Genexine price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Genexine returns is essential to provide solid investment advice for Genexine.
| Mean Return | -0.26 | Value At Risk | -4.38 | Potential Upside | 2.96 | Standard Deviation | 4.84 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Genexine historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Genexine Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Genexine or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Genexine's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Genexine stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.22 | |
β | Beta against Dow Jones | -0.4 | |
σ | Overall volatility | 5.01 | |
Ir | Information ratio | -0.08 |
Genexine Volatility Alert
Genexine exhibits very low volatility with skewness of 4.12 and kurtosis of 23.88. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Genexine's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Genexine's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Genexine Fundamentals Vs Peers
Comparing Genexine's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Genexine's direct or indirect competition across all of the common fundamentals between Genexine and the related equities. This way, we can detect undervalued stocks with similar characteristics as Genexine or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Genexine's fundamental indicators could also be used in its relative valuation, which is a method of valuing Genexine by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Genexine to competition |
| Fundamentals | Genexine | Peer Average |
| Return On Equity | -10.06 | -0.31 |
| Return On Asset | -0.0172 | -0.14 |
| Profit Margin | 0.01 % | (1.27) % |
| Operating Margin | (0.41) % | (5.51) % |
| Current Valuation | 2.14 T | 16.62 B |
| Shares Outstanding | 20.55 M | 571.82 M |
| Shares Owned By Insiders | 21.02 % | 10.09 % |
| Shares Owned By Institutions | 7.17 % | 39.21 % |
| Price To Sales | 10.84 X | 11.42 X |
| Revenue | 36.83 B | 9.43 B |
| Gross Profit | 9.76 B | 27.38 B |
| EBITDA | (14.76 B) | 3.9 B |
| Net Income | (48.56 B) | 570.98 M |
| Cash And Equivalents | 27.8 B | 2.7 B |
| Cash Per Share | 687.14 X | 5.01 X |
| Total Debt | 40.79 B | 5.32 B |
| Debt To Equity | 31.90 % | 48.70 % |
| Current Ratio | 2.26 X | 2.16 X |
| Book Value Per Share | 3,270 X | 1.93 K |
| Cash Flow From Operations | (12.75 B) | 971.22 M |
| Earnings Per Share | (1,283) X | 3.12 X |
| Target Price | 121750.0 | |
| Number Of Employees | 123 | 18.84 K |
| Beta | 0.88 | -0.15 |
| Market Capitalization | 318.55 B | 19.03 B |
| Total Asset | 636.86 B | 29.47 B |
| Retained Earnings | (28.44 B) | 9.33 B |
| Working Capital | 6.5 B | 1.48 B |
| Current Asset | 11.66 B | 9.34 B |
| Current Liabilities | 5.16 B | 7.9 B |
| Z Score | 4.2 | 8.72 |
| Net Asset | 636.86 B |
Genexine Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Genexine . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 0.0583 | |||
| Daily Balance Of Power | (0.58) | |||
| Rate Of Daily Change | 0.97 | |||
| Day Median Price | 5990.0 | |||
| Day Typical Price | 5940.0 | |||
| Market Facilitation Index | 360.0 | |||
| Price Action Indicator | (255.00) | |||
| Period Momentum Indicator | (210.00) |
About Genexine Buy or Sell Advice
When is the right time to buy or sell Genexine? Buying financial instruments such as Genexine Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Genexine in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Precious Metals ETFs Thematic Idea Now
Precious Metals ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Precious Metals ETFs theme has 28 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Precious Metals ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Genexine Stock
Genexine financial ratios help investors to determine whether Genexine Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Genexine with respect to the benefits of owning Genexine security.